Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,361 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,753 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06600022 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 441 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06761651 | A Study of TAVO412 in Patients with Cancer (TAVO412) | recruiting | Phase 1 | 50 | Tavotek BiotherapeuticsINDUSTRY | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06778603 |
| B7-H3 NIR Imaging for Osteosarcoma Surgery(ROLN-B7-H3) |
| recruiting |
| Phase 1 / Phase 2 |
| 32 |
| Peking University People's HospitalOTHER |
| 1 |
| Jan 16, 2025 |
| clinicaltrials |
| NCT06779045 | A Study of AK-1286 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 16, 2025 | clinicaltrials |
| NCT06186414 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC | recruiting | Phase 1 | 152 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06581419 | A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 78 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06703255 | A Phase 2 Study of HX301 in Patients with High-grade Giloma | recruiting | Phase 1 / Phase 2 | 72 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06776757 | Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 30 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06776770 | A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer(GC-Ib/II) | recruiting | Phase 1 / Phase 2 | 52 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05488548 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 75 | Epigenetix, Inc.INDUSTRY | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06770296 | The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study | recruiting | Phase 1 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06770764 | Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 50 | Trutino Biosciences Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06770881 | JSKN033 in Chinese Subjects with Advanced Malignant Tumors | not yet recruiting | Phase 1 / Phase 2 | 430 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 0 | Jan 13, 2025 | clinicaltrials |
| NCT06572813 | Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer(CISPD-7) | recruiting | Phase 1 / Phase 2 | 63 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06768151 | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer | recruiting | Phase 1 | 48 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06732531 | Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 1 / Phase 2 | 48 | Zhuhai Beihai Biotech Co., LtdINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT06643754 | A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors | recruiting | Phase 1 / Phase 2 | 115 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06763159 | A Study of HS-20124 in Patients with Advanced Solid Tumors | recruiting | Phase 1 | 450 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jan 8, 2025 | clinicaltrials |
| NCT06764836 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 108 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | recruiting | Phase 1 / Phase 2 | 168 | OncoResponse, Inc.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06686745 | Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 130 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06760676 | A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy | not yet recruiting | Phase 1 | 90 | Anhui Provincial HospitalOTHER_GOV | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06761027 | mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Provincial HospitalOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT05054257 | CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma(UHKT-CAR19-01) | recruiting | Phase 1 | 10 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06758713 | Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies | recruiting | Phase 1 | 60 | The Third Affiliated Hospital of Southern Medical UniversityOTHER_GOV | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06759181 | Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) | recruiting | Phase 1 / Phase 2 | 20 | Xuzhou Medical UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06760117 | UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors | recruiting | Phase 1 | 39 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05417321 | A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 80 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 2 | Jan 3, 2025 | clinicaltrials |
| NCT06734871 | A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma(CT1190B) | recruiting | Phase 1 | 24 | Aibin Liang，MD，Ph.D.OTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT06757335 | A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 204 | Hinova Pharmaceuticals Inc.INDUSTRY | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06757387 | Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 45 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 3, 2025 | clinicaltrials |
| NCT06755242 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 90 | Chinese PLA General HospitalOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06752785 | CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. | recruiting | Phase 1 | 10 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752447 | A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 | 94 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05954091 | OH2 Administered by Intratumoral Injection | not yet recruiting | Phase 1 | 29 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06404905 | Clinical Trial of BT02 in Patients With Advanced Solid Tumors(BT02) | recruiting | Phase 1 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06748872 | EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma(EPITOME-1015-I) | not yet recruiting | Phase 1 | 55 | Medigene AGINDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06689540 | Mts105 for Advanced Hepatocellular Carcinoma(MTS105 for HCC) | recruiting | Phase 1 | 14 | Shen LinOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Jan 16, 2025source: clinicaltrials